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Occult hepatitis B virus (HBV) infection has been re-
ported in 30% to 50% of patients with acute liver failure
(ALF) in small case series. The aim of this study was to
determine the prevalence of occult HBV infection in a large
series of ALF patients in the United States and the preva-
lence of precore and core promoter variants in patients with
ALF caused by hepatitis B. Sera from patients in the US ALF
study and liver, when available, were tested using nested
polymerase chain reaction (PCR) with primers in the HBV S
and precore regions. PCR-positive samples were sequenced.
Sera and/or liver from 139 patients (39 males, 100 females;
mean age, 42 years) enrolled between January 1998 and
December 1999 were studied. Twelve patients were diag-
nosed with hepatitis B, 1 with hepatitis B1C1D coinfec-
tion, and 22 had indeterminate etiology. HBV DNA was
detected in the sera of 9 (6%) patients; all 9 had ALF caused
by hepatitis B. HBV genotypes A, B, C, and D were present in
4, 3, 1, and 1 patients, respectively. Seven of these 9 patients
had precore and/or core promoter variants. Liver from 19
patients were examined. HBV DNA was detected in the liver
of 3 patients with ALF caused by hepatitis B, but in none of
the remaining 16 patients with non-B ALF. Contrary to ear-
lier reports, occult HBV infection was not present in this
large series of ALF patients in the United States. HBV pre-
core and/or core promoter variants were common among US
patients with ALF caused by hepatitis B. (HEPATOLOGY 2001;
33:972-976.)
There are approximately 2,000 cases of acute liver failure
(ALF) in the United States each year.1 A retrospective analysis
of 295 cases found that acetaminophen overdose was the most
common etiology of ALF in the US.2 In this series, 10% had
hepatitis B and 15% had no identifiable cause.
Several studies reported that some patients with ALF, de-
spite testing negative for hepatitis B surface antigen (HBsAg)
and hepatitis B core antibody immunoglobulin M (anti-HBc
IgM), had detectable hepatitis B virus (HBV) DNA in the se-
rum or liver using polymerase chain reaction (PCR) assays.3-8
In these patients, the etiology of ALF may be related to occult
hepatitis B infection. The prevalence of occult hepatitis B in-
fection in patients with non-A, non-B ALF has been reported
to vary from a low of 0% to 4% in Europe9-12 to 50% in Ja-
pan.3-5 Available data on the prevalence of occult hepatitis B
infection among patients with ALF in the US are conflicting
and based on very few studies in a small number of patients.
The prevalence of occult hepatitis B infection in patients with
ALF was reported to be 30% to 50% in 3 studies that involved
a total of 31 patients,6-8 but absent in 2 other studies that
involved a total of 23 patients.13,14 Studies that examined both
sera and liver tissues invariably reported higher rates of HBV
detection in the liver.3,4,7 Liver tissues were tested in 4 of the 5
US studies cited.
Among patients with ALF secondary to hepatitis B infection
(ALF-B), an association between mutations in the precore and
core promoter region of the HBV and a fulminant course of the
disease has been reported. HBV precore stop codon variants
had been detected in 88% to 100% of patients with ALF in
Japan,15,16 83% in Israel,17 36% in Taiwan,18 10% in France,19
and only 5% in the US.20 A subsequent study found that only
7% of patients with ALF in the US had predominant precore
variants, but 53% had a mixture of precore variants and wild-
type HBV.21 The low frequency of precore variants in the US is
thought to be related to the predominance of HBV genotype A,
which precludes the selection of the G-to-A change at nucle-
otide 1896.22 HBV core promoter variants had been found in
68% to 72% of patients with ALF-B in Japan,23,24 and in 30% to
78% in Germany.25,26 The data on prevalence of core pro-
moter variants in patients with ALF in the US are limited. A
single US study reported that 10% of patients with ALF-B had
core promoter variants.27
The aims of this study were to determine the prevalence of
occult hepatitis B infection in a large cohort of patients with
ALF in the US and to determine the prevalence of HBV precore
and core promoter variants among US patients with ALF sec-
ondary to hepatitis B.
PATIENTS AND METHODS
Materials
Serum samples were prospectively collected from patients pre-
senting with ALF of any etiology to the 14 academic centers partici-
pating in the US ALF Study Group (see Appendix). All but 1 are liver
transplantation centers. ALF was defined as the presence of coagu-
lopathy (prothrombin time .15 seconds or international normalized
ratio .1.5) and the onset of hepatic encephalopathy within 8 weeks
of the first symptoms or jaundice in an individual without underlying
liver disease.28 Serum samples were collected on the day of presen-
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tation and daily for 7 days. Samples at presentation and, when avail-
able, a second specimen collected between days 2 to 7 were tested for
HBV DNA. All the serum samples were stored at 280°C before test-
ing. Collection of liver tissues was not included in the ALF study
protocol. Liver specimens, when available at autopsy or transplanta-
tion, were retrieved as formalin-fixed, unstained sections and tested
for HBV DNA. Both the serum samples and liver tissues were tested
under code in Dr. Lok’s laboratory at the University of Michigan
Medical Center. Each center provided detailed demographic, clini-
cal, laboratory, and outcome information for all patients enrolled.
Etiologic categories were defined by each study center, based on
accepted diagnostic criteria that were circulated to all investigators.
The etiology was attributed to hepatitis B when HBsAg and/or anti-
HBc IgM were positive. The diagnosis of indeterminate etiology was
made when extensive history, clinical evaluation, and laboratory
tests failed to reveal a diagnosis. All patients’ data were collected at
the individual sites and sent to the central site at University of Texas
Southwestern Medical Center (UTSW). Data were then entered into
an Access (Microsoft) database by staff of the Academic Computing
Department at UTSW. This study was approved by the Institutional
Review Boards of all centers involved. Informed consent was ob-
tained from the next of kin, because patients had altered mentation as
an entry criterion. Information on the demographic data, clinical
etiology, serologic markers of hepatitis A, B, and C, and outcome of
the patients were released by the ALF study coordinating center after
the HBV-DNA test results by PCR were reported.
PCR Assays for HBV DNA
Serum Samples. Serum samples were tested for HBV DNA by
nested PCR assay using primers to amplify 2 different regions of the
HBV genome: the precore/core region and the surface region as de-
scribed previously.29,30 All necessary precautions were taken to pre-
vent cross-contamination. Negative controls using sterile water in-
stead of DNA extract and positive controls using cloned plasmids
containing the whole HBV-DNA genome were run with every batch
of serum samples. The sensitivity limit of our PCR assay is 250 to 500
copies of HBV DNA per milliliter.29 Samples with no detectable HBV
DNA were retested using twice as much first-round PCR product.
Liver Tissues. Liver specimens from 19 patients were available for
analysis. DNA was extracted using the Ex-Wax DNA Extraction Kit
(Intergen Co., Purchase, NY) according to the manufacturer’s in-
structions. Explanted liver tissues from 2 patients with hepatitis B
were used as positive controls for DNA extraction and subsequent
PCR. Explanted liver tissues from 2 patients with primary biliary
cirrhosis and no serologic marker of HBV infection were used as
negative controls. Because of the limited availability of liver tissue
(1-3 sections) from the study patients, PCR was performed using one
set of primers from the precore/core promoter region only. We were
able to detect HBV DNA from the positive controls with as little as
1/10 of the DNA extract from one section (5 mm thick) of liver tissue.
To optimize the yield in the study patients, we used 3 to 10 times as
much DNA extract and 5 to 10 times as much first-round PCR prod-
uct compared with the minimal amount required for the detection of
HBV DNA in our positive controls.
Sequencing of HBV Genome
Amplified PCR products from serum samples or liver tissues were
purified by Qiaquick spin columns (Qiagen Inc., Chatworth, CA)
and analyzed by direct sequencing using the standard protocol for
the Applied Biosystems DNA sequencer 373A (Perkin-Elmer Corp.,
Foster City, CA). Primers SS2 (59-39 nucleotide 61-75) and SAS2
(59-39 nucleotide 991-970) were used for direct sequencing of the S
gene, and P1 (59-39 nucleotide 1604-1623) and P2 (59-39 nucleotide
2076-2060) were used for the precore/core promoter region.29,30 The
DNA sequences of the S gene were compared with published se-
quences in Genbank to determine the HBV genotypes.
RESULTS
Demographics of the Patients Studied. Between January 1998
and December 1999, 179 patients were enrolled in the US ALF
study. Forty patients did not have stored serum sample or
liver tissue and were excluded from this study. Of the 139
patients (78% of the entire series) studied, 39 were males and
100 were females. The mean (6SD) age was 42 6 14 years.
There were 101 whites, 20 Hispanics, 9 African Americans, 5
Native Americans, 3 Asians, and 1 patient of unknown race.
Paired serum samples were available in 108 patients, includ-
ing 7 patients with ALF-B and 101 patients with non-B ALF.
Clinical Etiology of ALF. The most common clinical etiology
in our cohort of ALF patients was acetaminophen overdose
(34%) (Table 1). Twenty-two patients (16%) appeared to have
no clear etiology. ALF-B was diagnosed in 12 patients (9%).
One patient had triple viral infection with hepatitis B, C,
and D.
HBV-DNA Detection in Serum Samples. HBV DNA was de-
tected using PCR assay in serum samples from 9 (6%) pa-
tients. All 9 patients had a clinical diagnosis of ALF-B and
detectable HBV DNA using both sets of primers. Five of these
9 patients had follow-up samples. HBV DNA remained detect-
able in 2 (40%) patients, 2 to 5 days after presentation. HBV
DNA was not detected in the remaining 3 patients with ALF-B
nor in the patient with triple viral infection. Six patients with
ALF-B were tested for HBV DNA by non-PCR based assays at
the participating centers: none tested positive. Four (67%) of
these 6 patients had detectable HBV DNA by our PCR assay.
HBV DNA could not be detected in any of the 126 patients
with non-B ALF, including 22 patients with indeterminate
etiology. Anti-HBc IgG was tested in 98 patients with non-B
ALF: only 7 (7%) tested positive.
HBV-DNA Detection in Liver Tissue. Of the 19 patients with
liver specimens, 8 patients had indeterminate etiology, and 3
had ALF-B (Table 2). HBV DNA was detected in the liver
tissues from all 3 patients with ALF-B, but in none of the 16
patients with non-B ALF. Fifteen of the 16 patients with non-B
ALF were tested for anti-HBc IgG: none tested positive. Serum
TABLE 1. Clinical Etiology of ALF and Prevalence of HBV Markers











Acetaminophen overdose 47 (34) 0 0/2 0/42 0/15 5/35
Indeterminate 22 (16) 0 0/8 0/21 0/12 0/17
Drug-induced 21 (15) 0 0/3 0/20 0/6 1/16
Hepatitis A 8 (6) 0 0/0 0/8 0/3 1/5
Hepatitis B 12 (9) 9 3/3 10/12 11/12 7/8
Hep B 1 C 1 D 1 (0.7) 0 0/0 1/1 0/1 0/1
Miscellaneous 28 (20) 0 0/3 0/25 0/13 0/24
Total 139 9 3/19 11/129 9/60 14/106
HEPATOLOGY Vol. 33, No. 4, 2001 TEO ET AL. 973
samples were not available in 2 patients who had stored liver
tissue. The results on the liver and serum specimens were
concordant in the remaining 17 patients.
HBV Genotyping and Sequencing. Of the 9 patients with
ALF-B, 4 were infected with HBV genotype A, 3 with genotype
D, 1 with genotype B, and 1 with genotype C.
Analysis of the precore region revealed mutations in 6 pa-
tients (Table 3). Four had the commonly described precore
stop-codon mutation, eW28X/G1896A (TGG to TAG). One pa-
tient also had a precore stop-codon mutation at position 28,
but the G-to-A change involved nucleotide 1897, eW28X/
G1897A (TGG to TGA). The remaining patient had a precore
start-codon mutation, G1817T (ATG to ATT). All 6 patients
were hepatitis B e antigen (HBeAg)-negative. All patients ex-
cept the one with the eW28X/G1897A (TGG to TGA) mutation
were infected with non-A HBV genotypes.
Mutations in the core promoter region were seen in 3 pa-
tients (Table 3). Two patients had the dual mutations A1762T
and G1764A, and 1 patient had the G1764A mutation only. The
latter patient had 2 other mutations, C1766T and T1768A, in the
core promoter region. Two patients had concomitant muta-
tions in the precore region. The third patient who had muta-
tion in the core promoter region only was HBeAg-positive.
Overall, 7 of the 9 (78%) patients with fulminant hepatitis B
had mutations in the precore or core promoter region.
Analysis of the HBV S gene did not reveal any consistent
mutations. Most of the changes were at sites that are polymor-
phic across the HBV genotypes. None of the remaining
changes were detected in more than 1 of the 9 patients stud-
ied.
DISCUSSION
In our study, which represents the largest series of consec-
utive patients with ALF in the United States,6-8,13,14 we could
not find a single case of occult hepatitis B infection. Several
studies have reported that using PCR assays, HBV DNA may
be detected in the serum of individuals who have recovered
from prior hepatitis B infection.31 The low rate of occult hep-
atitis B infection observed in our study and in a similar study
of Sallie et al.,10 compared with reports from Japan, may be
related to a lower prevalence of past HBV infection in the
United States and England. In support of this hypothesis, only
7% of the patients in our study with non-B ALF tested positive
for anti-HBc IgG. While the low rate of detection of occult
hepatitis B infection might be related to the relative insensi-
tivity of our PCR assays, our standard PCR assay has a detec-
tion limit of 250 to 500 copies of HBV DNA per milliliter of
serum or 25 to 50 copies of HBV DNA per assay. This is
comparable with commercially available PCR assays. In addi-
tion, all the samples that tested negative were retested using
2-fold higher concentrations of DNA. Therefore, it is unlikely
that low sensitivity of the PCR assay accounts for the negative
results.
Mutations in the HBV genome may be present, especially in
patients with occult hepatitis B infection. To ensure optimal
detection of HBV DNA, we performed nested PCR using prim-
ers from 2 regions of the HBV genome. All the samples that
tested positive had concordant results using both sets of prim-
ers. In this study, HBV DNA was detected in the sera of 9
(75%) and in the liver tissues of all 3 patients with ALF-B.
These rates of detection are similar to other published re-
ports.21
Patients with ALF-B have rapid viral clearance.32 Failure to
detect HBV DNA in the sera of 3 patients with ALF-B may be
related to rapid viral clearance or late referral of patients to the
participating sites. Of the 7 ALF-B patients with follow-up
samples, 2 had undetectable HBV DNA at presentation. In the
remaining 5 patients with HBV DNA in serum at presentation,
HBV DNA became undetectable in 3 (60%) patients after 3 to
6 days, illustrating the rapidity of viral clearance in patients
with ALF-B. Several studies reported that coinfection with
hepatitis C or D virus may interfere with HBV replication.33
Viral interference may account for the lack of detectable HBV
DNA in the patient with triple hepatitis virus infection.
Previous studies on patients with occult hepatitis B infec-
tion found that HBV DNA is more often detected in liver
tissues than in sera.3,4,7 Unfortunately, liver tissues are rarely
available in patients with ALF. In this study, liver specimens
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2 N P P P P P N
3 P P P N P N
TABLE 3. HBV Genotypes, Precore, and Core Promoter Changes in Patients With Fulminant Hepatitis B
Patient






1 White M 54 Neg D A G A
2 White M 63 Neg C A G A
3 Black M 50 Pos A A G G
4 White F 17 Neg D A G G1817T
5 Black F 43 Pos A T A G
6 Asian F 62 Neg B A G A
7 White M 58 Pos A A G G
8 White M 62 Neg D T A A
9 White F 30 Neg A A A G1897A
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were available for analysis in 19 (14%) patients only. The low
percent of patients with liver specimens was related to the fact
that collection of liver tissues was not included in the ALF
study protocol. HBV DNA was detected in the liver tissues of
all 3 patients with ALF-B, but in none of 16 patients with
non-B ALF. These 3 patients underwent transplantation on
days 2, 5, and 7 after presentation. Follow-up serum was not
available in the first patient, but in the latter 2, sera collected
on days 5 and 6 of illness, respectively, tested negative for
HBV DNA by PCR. The lack of liver tissues for analysis in 86%
of the study patients may have resulted in an underestimation
of the prevalence of occult hepatitis B infection. Despite these
limitations, our sample size of 19 liver specimens is larger
than other published reports.6,7,8,12 Thus, we believe that oc-
cult hepatitis B infection is extremely rare among patients
with ALF in the US.
Precore stop-codon variants had been previously reported
to be rare in the US, because the predominant HBV genotype
A precludes the development of the G1896A mutation. How-
ever, we found that 6 (67%) of 9 patients with ALF-B had
precore variants. Four of these 6 patients had the classical
G1896A change. The high prevalence of precore stop-codon
variant among our patients may be related to the diversity of
HBV genotypes, with 5 (56%) patients infected with geno-
types B, C, and D, which permit the selection of the G1896A
mutation. The diversity of HBV genotypes and a higher prev-
alence of precore stop-codon variants in our study compared
with previous US studies20,21 may be related to the fact that
our study recruited patients from 14 centers across the United
States. These “differences” may also be related to the small
sample size in all studies performed to date, including our
study. Core promoter variants were also reported to be rare in
ALF patients in the United States.27 Precore or core promoter
variants were found in 78% of our patients. Mutations in the
core promoter region involving C1766T and T1768A had been
reported to enhance HBV replication.34 These mutations were
seen in 1 of our patients. Because of the small number of
patients with ALF-B and the lack of controls with self-limited
acute hepatitis B, we cannot determine if the precore and core
promoter mutations are more prevalent in patients with a
fulminant course.
In summary, based on our study of a large cohort of ALF
patients, occult HBV infection is extremely rare in patients
presenting with ALF in the United States. In fact, we did not
detect a single case of occult hepatitis B infection in this study.
Among patients with ALF-B, mutations in the precore and
core promoter region were common. However, the relation
between these mutations and the course of the hepatitis is not
clear, because precore and core promoter variants have been
found in inactive carriers as well as in patients with chronic
liver disease.
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